<DOC>
	<DOCNO>NCT00056290</DOCNO>
	<brief_summary>This gene therapy study conduct evaluate intramuscular gene transfer use VEGF ( Vascular Endothelial Growth Factor ) patient diabetic neuropathy leg . This condition cause decrease feel sensation due diabetes . VEGF DNA , genetic material inject muscle leg . Once leg , show cause new blood vessel grow variety condition .</brief_summary>
	<brief_title>VEGF Gene Transfer Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Inclusion criterion : To eligible enroll remain study , patient must meet following criterion : Be least 21 year old . Have type I type II diabetes mellitus require oral antihyperglycemic agent insulin . Have peripheral neuropathy relate diabetes . Exclusion criteria Patients exclude trial follow condition meet : Have history cancer ( nonmelanoma skin cancer insitu cervical cancer ) last five year . Be unable meet study requirement , include approximately 79 outpatient visit 12 month period .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Peripheral Artery Disease</keyword>
</DOC>